Literature DB >> 10825139

Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53.

B R Dix1, S J O'Carroll, C J Myers, S J Edwards, A W Braithwaite.   

Abstract

The use of an Elb55k-deficient adenovirus, ONYX-015, to selectively target tumor cells containing a mutated p53 gene has produced promising results. However, recent reports have questioned the selectivity of this virus, showing that ONYX-015 can replicate in cells containing a wild-type p53 and that p53 may actually be required for cell death. To address these apparent contradictions in the literature, we infected a number of mutant and wild-type p53-containing cell lines with ONYX-015 and wild-type adenovirus and observed their death profiles up to 10 days postinfection. We demonstrate that two distinct cell death phenotypes exist, one of which is rapid and dependent on the presence of p53 and one of which is p53 independent. Using adenoviruses expressing E1b55k proteins deficient in their ability to bind p53, we show that formation of a complex between p53 and the adenoviral Elb55k protein is necessary for the activation of the rapid cell death pathway. In the absence of p53 or the absence of complex formation between p53 and Elb55k, cell death is delayed considerably. These data suggest three things: that the selectivity of killing appears to be dependent on the presence of the E1b55k/p53 complex; that viruses lacking Elb55k (such as ONYX-015) kill cells in a delayed manner independent of p53; and that binding of E1b55k to p53 does not merely serve to inactivate p53, but rather is required for the induction of rapid cell death. The components of this complex that lead to rapid cell death remain to be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10825139

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?

Authors:  B R Dix; S J Edwards; A W Braithwaite
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

Authors:  Sara J Edwards; Brett R Dix; Colleen J Myers; Deirdre Dobson-Le; Lily Huschtscha; Merilyn Hibma; Janice Royds; Antony W Braithwaite
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Adenovirus E1B 55-kilodalton protein is required for both regulation of mRNA export and efficient entry into the late phase of infection in normal human fibroblasts.

Authors:  Ramon Gonzalez; Wenying Huang; Renee Finnen; Courtney Bragg; S J Flint
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

4.  p53-expressing conditionally replicative adenovirus CNHK500-p53 against hepatocellular carcinoma in vitro.

Authors:  Hong-Chuan Zhao; Qi Zhang; Yang Yang; Min-Qiang Lu; Hua Li; Chi Xu; Gui-Hua Chen
Journal:  World J Gastroenterol       Date:  2007-02-07       Impact factor: 5.742

5.  Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death.

Authors:  Mohamed A I Abou El Hassan; Ida van der Meulen-Muileman; Saman Abbas; Frank A E Kruyt
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  A novel Bcl-2-like inhibitor of apoptosis is encoded by the parapoxvirus ORF virus.

Authors:  Dana Westphal; Elizabeth C Ledgerwood; Merilyn H Hibma; Stephen B Fleming; Ellena M Whelan; Andrew A Mercer
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

7.  The p53 protein does not facilitate adenovirus type 5 replication in normal human cells.

Authors:  Jasdave S Chahal; S J Flint
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

8.  Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.

Authors:  Florian Kühnel; Engin Gürlevik; Thomas C Wirth; Nina Strüver; Nisar P Malek; Martina Müller-Schilling; Michael P Manns; Amancio Carnero; Lars Zender; Stefan Kubicka
Journal:  Mol Ther       Date:  2009-12-29       Impact factor: 11.454

9.  Adenoviral vector-based strategies for cancer therapy.

Authors:  Anurag Sharma; Manish Tandon; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Drug ther       Date:  2009-05-01

Review 10.  ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.

Authors:  S Ries; W M Korn
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.